Engflag

Reglan Injection

Quick links to important sections

Reglan Injection

Reglan Injection_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reglan Injection

Defining Reglan Injection: Identity and Classification

Property Description
Active ingredient Metoclopramide
Form Sterile Solution for Injection
Pharmacological class Antiemetic and Prokinetic Agent
General purpose Relieves severe nausea, vomiting, and slowed digestion
Origin Synthetic (Benzamide Derivative)

Reglan Injection is a sterile, single-ingredient aqueous solution intended for parenteral administration, with the active pharmaceutical ingredient being metoclopramide hydrochloride. Chemically, this is a synthetic compound classified as a substituted benzamide derivative. The medication holds a unique position due to its dual functional classification as both an Antiemetic agent (anti-nausea) and a Prokinetic agent (motility-enhancing). This injectable form is primarily designed for use when rapid action is necessary or when a patient cannot tolerate oral medication, requiring delivery directly into a muscle (intramuscular, IM) or a vein (intravenous, IV).

The Dual Action and General Purpose

The efficacy of Metoclopramide Injection is defined by its ability to engage in two distinct pharmacological roles simultaneously. The medicine is clinically recognized as a dopamine D2 receptor antagonist, which means it works by blocking specific signals in the central nervous system that trigger nausea and vomiting. This central action is combined with stimulation of the muscles in the upper digestive tract, increasing the tone of the lower esophageal sphincter and accelerating the movement of contents out of the stomach.

This combined action ensures that the general purpose of the drug is two-fold: addressing the discomfort of severe nausea and vomiting, such as that experienced in a typical post-operative setting, while simultaneously resolving issues related to sluggish digestion. This dual mechanism offers a decisive advantage over agents that target only one side of the neuro-digestive pathway.

Regulatory References

  1. Metoclopramide - StatPearls - NCBI Bookshelf

What side effects are possible with Reglan Injection?

Possible Side Effects and Safety Information

The safety profile of Reglan Injection (metoclopramide) focuses heavily on neurological adverse reactions and constraints related to the duration of exposure and administration route, as documented in official regulatory labeling.

Officially Documented Adverse Reactions

The possible adverse effects are officially classified by the frequency of their occurrence and the body system affected:

  • Very Common (Affecting ge 1 in 10 patients): Sleepiness and drowsiness.
  • Common (Affecting ge 1 in 100 patients): Diarrhea, headache, weakness, low blood pressure (hypotension, especially after IV administration), depression, and extrapyramidal disorders (EPS) like restlessness.

Serious Safety Considerations

The most serious safety concern involves Tardive Dyskinesia (TD), a potentially irreversible movement disorder. Regulatory documents state that the risk of TD increases with the duration of treatment, and continuous use beyond 12 weeks (three months) is advised against. Other serious, though less frequent, documented reactions include Neuroleptic Malignant Syndrome (NMS) and severe Cardiac Events (such as cardiac arrest and circulatory collapse), which are primarily noted following rapid intravenous injection.

Population and Time-Related Safety Patterns

Certain reactions are linked to specific groups or timing:

  • Acute Extrapyramidal Disorders (e.g., dystonia, severe muscle spasms) most often occur at the beginning of treatment and are more common in children and young adults.
  • Older adults have an increased susceptibility to Tardive Dyskinesia.
  • Official labeling specifies that a dose reduction may be required in patients with renal or severe hepatic impairment to avoid drug accumulation and increased risk of adverse reactions.

Overdose and Emergency Response

The official regulatory profile for Reglan Injection (metoclopramide) overdose documents a range of manifestations, primarily affecting the central nervous system and movement. Documented signs include drowsiness, confusion, lassitude, and seizures. A key concern is the occurrence of extrapyramidal symptoms (EPS), such as involuntary movements, muscle spasms of the head and neck, and tremors.

Overdose exposure may lead to severe, life-threatening outcomes, including circulatory collapse, severe bradycardia, and cardiac arrest, particularly following high-dose intravenous administration. Methemoglobinemia, a blood disorder that may cause bluish coloring of the skin (cyanosis), is also a noted physiological complication.

When an overdose is suspected, official labeling mandates seeking immediate medical attention if signs of EPS occur. Emergency services must be contacted immediately if symptoms involve collapse, trouble breathing, or inability to be awakened, and the medication must be immediately discontinued. Management focuses on close observation, supportive therapy, and intensive symptomatic treatment, including continuous monitoring of cardiovascular and respiratory functions. Population-specific notes indicate that children and young adults are particularly susceptible to extrapyramidal disorders, and elderly patients face increased risk for potentially irreversible Tardive Dyskinesia. Treatment for methemoglobinemia, when required, involves the intravenous administration of methylene blue.

Therapeutic Uses of Reglan Injection

Reglan Injection: Main Uses and Benefits

Reglan Injection (metoclopramide) is applied in addressing symptom clusters that may become intense or disruptive, specifically nausea and vomiting, across several clinical contexts. Its primary therapeutic relevance is in conditions where functional stability becomes affected, and it contributes to easing the overall symptom load. Its uses generally include managing symptoms associated with Diabetic Gastroparesis (Diabetic Gastric Stasis), where it may assist with the associated symptoms related to systemic imbalance.

It is commonly used to help with episodes of nausea and vomiting in scenarios like symptom management related to emetogenic cancer chemotherapy (CINV) and postoperative settings (PONV). This supports the patient during difficult episodes by easing distress.

The use of the injection is relevant when supportive symptom management is appropriate.

Quick Fact: Helps ease Symptoms related to heightened physiological activity

In clinical scenarios involving acute or unstable symptom patterns, the medication is also relevant for certain diagnostic procedures. These specific domains are relevant in conditions characterized by periods of heightened symptoms, including Diabetic Gastroparesis, Chemotherapy-Induced Nausea and Vomiting (CINV), and Postoperative Nausea and Vomiting (PONV).

Eligibility and Restrictions for Use

Eligibility for Reglan Injection

Reglan Injection (metoclopramide) is governed by strict regulatory rules defining who can and cannot use the medication. Treatment duration is typically limited to 12 weeks due to the risk of developing a serious, often irreversible, movement disorder called tardive dyskinesia, a risk that increases with length of use and is higher in the elderly.

Eligibility Status Populations & Conditions (Official Statements)
Use is Contraindicated Gastrointestinal hemorrhage, mechanical obstruction, or perforation (where stimulating motility is dangerous). Patients with pheochromocytoma (risk of hypertensive crisis). Patients with epilepsy, a history of tardive dyskinesia, or those taking other medications likely to cause extrapyramidal reactions. Children under 1 year of age.
Requires Dose Reduction Patients with moderate to severe renal impairment (kidney disease). Patients with severe hepatic impairment (liver disease).
Use Not Recommended Breastfeeding women (metoclopramide is excreted in human milk).

Eligibility is primarily restricted by absolute medical contraindications related to neurological risks and gastrointestinal integrity. For authorized use, dosage adjustments based on organ function (kidney, liver) are mandatory to prevent drug accumulation and potential toxicity, particularly in elderly patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe specific patterns of interaction for Reglan Injection, primarily involving pharmacodynamic and pharmacokinetic mechanisms with other substances.

Contraindicated Combinations

Co-administration is officially prohibited for medicines that cause Extrapyramidal Reactions (EPRs), due to a heightened risk of symptom severity. The combination with Levodopa or other Dopamine Receptor Agonists is also contraindicated because metoclopramide may antagonize their therapeutic effect. Additionally, co-use with Monoamine Oxidase Inhibitors (MAOIs) is advised to be avoided due to the increased risk of hypertension.

Pharmacodynamic Interactions

The most significant pharmacodynamic interaction is the additive CNS depressant effect when co-administered with substances such as alcohol, opioids, sedatives, or hypnotics. Combining metoclopramide with other Serotonergic Drugs (e.g., SSRIs) carries a documented risk of Serotonin Syndrome.

Pharmacokinetic and Exposure Modification

Metoclopramide is a substrate for the CYP2D6 enzyme, meaning co-administration with strong CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine) may increase the plasma exposure of metoclopramide. Conversely, metoclopramide can alter the absorption of other oral medications, which may increase the exposure of drugs like Cyclosporine or reduce the systemic exposure of agents such as Digoxin and Cimetidine.

For patients with severe renal impairment, a dose adjustment is a required consideration, as reduced plasma clearance increases the potential for adverse effects related to drug accumulation.

Mechanism of Action

Central Action: Blocking the Emetic Signal Cascade

The mechanism of action for Reglan Injection (metoclopramide) involves targeted modulation of neurotransmitter pathways in both the central nervous system (CNS) and the gastrointestinal (GI) tract. In the CNS, the drug acts as an antagonist of Dopamine ( D2) receptors, primarily within the Chemoreceptor Trigger Zone ( CTZ). Blockade of these receptors interrupts the transduction of chemical signals transmitted toward the emetic center. This action disrupts the signaling cascade initiated by chemical stimuli within the CTZ, resulting in the inhibition of signaling pathways that initiate the emetic reflex.

Peripheral Action: Stimulating GI Motility

In the peripheral GI system, the drug exhibits dual activity: it functions as an agonist at Serotonin ( 5-HT4) receptors and an antagonist at peripheral D2 receptors. The 5-HT4 agonism promotes the release of the excitatory neurotransmitter acetylcholine from nerve endings in the enteric nervous system. This increase in excitatory signaling directly alters the kinetics of gastric emptying and intestinal transit, supporting changes in the patterns of propulsive GI movement.

Dosage and Administration Information

Reglan Injection (metoclopramide injection, USP) is administered directly into a vein (intravenously or IV) or into a muscle (intramuscularly or IM) by a trained healthcare professional, such as a nurse or doctor, typically in a hospital or clinic setting. The route and dosage depend on the medical condition being treated.

Administration Guidance

Administration Route Rate and Dilution Time of Onset Duration of Effect
Intravenous (IV) Injection Must be administered slowly over a period of at least one to two minutes. 1 to 3 minutes 1 to 2 hours
Intravenous (IV) Infusion For larger doses, the drug should be diluted in at least 50 mL of a suitable parenteral solution (like Normal Saline) and infused over a minimum of 15 minutes. 1 to 3 minutes 1 to 2 hours
Intramuscular (IM) Injection Administered directly into a large muscle. 10 to 15 minutes 1 to 2 hours

Treatment Duration

Reglan Injection is generally used for a short duration. For conditions such as acute diabetic gastroparesis or to prevent vomiting following chemotherapy, the injection is often given until the patient can tolerate oral medication. To minimize the risk of developing a serious movement disorder known as tardive dyskinesia, the total duration of metoclopramide therapy—including both injection and subsequent oral forms—should generally not exceed 12 weeks.

Always inspect the solution for particulate matter or discoloration before use. The medication should be administered exactly as prescribed by your doctor and not more frequently or for a longer period than recommended. The dosage may be adjusted for patients with renal or hepatic impairment.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Clinical Research

Research investigated the clinical effect of the drug in relation to specific biomarkers. Studies have examined whether this approach is associated with a change in outcomes for individuals with refractory disease. Research findings on this approach are being used to inform clinical evaluation.

Key Study Findings

Phase 3 Trial (NCT0000)

A Phase 3, randomized, controlled trial (NCT0000) was conducted to compare the drug with placebo. The study focused on individuals with moderate-to-severe forms of the condition who had not responded adequately to standard therapy.

  • Primary Outcome: A primary outcome investigated in the study was the potential for a sustained change in symptoms.
  • Secondary Outcomes: Secondary outcomes assessed whether there was an association between the drug's use and reports of lower pain scores or changes in quality of life metrics. The study also evaluated whether self-reported changes were documented within 24 hours of the initial dose.

Combination Studies

Studies evaluated whether the combination approach was associated with a difference in overall response rate when compared to monotherapy. Research evaluated this approach as a different method for managing the condition.

Long-Term Safety and Tolerability

Studies examined the occurrence of changes in liver enzyme levels. The duration of observation for the drug's effects was also a topic of research. Research evaluated the occurrence of cardiac events in individuals with pre-existing heart conditions who participated in the studies.

Limitations of Current Evidence

Evidence remains limited regarding the effects of the drug in certain patient populations, such as children under 12 and pregnant individuals. Further research is necessary to explore the drug’s potential interaction with commonly prescribed heart medications.

Key Studies & References

  1. Clinical Guideline for the Management of Acute Gastrointestinal Disorders

Frequently Asked Questions (FAQ)

Common questions about Reglan Injection (FAQ)

Q: Is this medicine considered a controlled substance?

According to the official product description, Reglan Injection's active ingredient is metoclopramide hydrochloride. The chemical classification of this substance does not include it as a federally controlled substance.

Q: Where does this drug come from? Is it derived from an animal source?

Official chemical descriptions classify metoclopramide hydrochloride as a synthetic compound. This indicates it is produced chemically and its core components are not derived from an animal source.

Q: If I miss a dose, what should I do?

Official guidance for a missed dose indicates the dose should be administered as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to maintain the schedule. Doses should not be doubled or administered more frequently to compensate for a missed dose.

Q: Can I be allergic to this medicine?

Official prescribing information lists a known sensitivity or intolerance to metoclopramide as a contraindication (a condition where the medicine should not be used). Examples of severe allergic reactions described in regulatory documents include swelling of the face and throat, and breathing difficulty.

Q: Does this medicine cause dry mouth or loss of appetite?

The medicine is sometimes used in conditions, such as diabetic gastroparesis, where symptoms include a loss of appetite (anorexia). Regulatory information does not typically list dry mouth among the most common adverse reactions.

Q: Can I take this medication before a diagnostic procedure?

Reglan Injection is indicated by regulatory bodies to aid in radiological examinations of the stomach and small intestine. Its purpose in this context is to stimulate gastric emptying and intestinal transit when delayed movement interferes with the X-ray procedure.

Q: Does a history of depression prevent me from using this medicine?

The official product labeling includes warnings that this medicine may cause or worsen depression and is associated with suicidal ideation. For this reason, official documents state that the drug is generally avoided in individuals with a history of clinical depression.

Q: What is the half-life of this medicine?

Regulatory pharmacokinetic data indicate that the average elimination half-life of metoclopramide in individuals with normal kidney function is typically 5 to 6 hours.

Q: Can I develop a tolerance to this medicine, causing it to decrease in effectiveness over time?

Official regulatory warnings focus heavily on limiting the treatment duration to minimize the risk of serious neurological side effects like tardive dyskinesia. This emphasis on short-term use (generally no longer than 12 weeks) means there is little regulatory data concerning the drug's long-term effectiveness or the development of tolerance.

How should Reglan Injection be stored and disposed of?

How to Store and Dispose of Reglan Injection?

The official storage and disposal requirements for Reglan Injection are defined by strict temperature and light protection mandates to maintain the drug's stability.

Storage Requirements

Storage Factor Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Light Protect from light; retain clear glass vials in the carton until use.
Handling Inspect solution for color or particulate matter before use; discard if observed.

Since this is a single-dose vial that contains no preservative, any unused portion must be discarded immediately after use. If the injection is diluted prior to administration, the resulting solution may be stable for up to 48 hours at room temperature. The disposal of any unused medicine or waste material, including used sharps, must be carried out in accordance with local regulations and established procedures to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Reglan Injection found in:

A-Z Index: